Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

YOU WONT BELIEVE: Evoke pharma earnings perspective return on capital employed - What They Never Told You

According to Benzinga Pro data, during Q4, Evoke Pharma (NASDAQ:EVOK) posted sales of $360.57 thousand. Earnings were up 15.08%, but Evoke Pharma still reported an overall loss of $1.67 million. Evoke Pharma collected $930.45 thousand in revenue during Q3, but reported earnings showed a $1.97 million loss.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.